Falah Hassan Sheri, Hiba Dawood, Jubran K Hassan, Qais A. Aljazaeari
{"title":"2型糖尿病患者口服补充牛磺酸对体重影响的研究血糖控制和一些骨矿化生化指标","authors":"Falah Hassan Sheri, Hiba Dawood, Jubran K Hassan, Qais A. Aljazaeari","doi":"10.54634/2090-9101.1022","DOIUrl":null,"url":null,"abstract":"Background: Taurine is sulfur containing semi-essential amino acid that has important roles in many biological processes, but; its effects on glucose homeostasis, weight; growth and bone mineralization were not well defined in human. Objectives: evaluation the effects of oral taurine used for 3 months on bone mineralization biomarker; glycemic control and body weight in type II diabetic patients. Methods: interventional double-blind placebo-controlled study in which 80 patients with type2 diabetes mellitus (age range 45e55) assigned in either control (n 1⁄4 40) or study (n 1⁄4 40) group. The last group received 1000 mg capsule of taurine once a -d for three months. Parameters measured were serum calcium, 25(OH) vitamin D and osteocalcin, NTX-1; HbA1C% and Fasting blood glucose before and after 3 months. Results: Taurine led to significant (p < 0.05) rise in osteocalcin and significant lowering in Body weight and BMI and there were no significant changes in Serum Calcium; NTX-1; Vitamin D; HbA1C% and fasting blood glucose; all as compared with control values. Conclusion: 3 months of oral Taurine used in type II diabetic patients may modulate bone mineralization represented by elevation of osteocalcin; and reduction of body weight, but has no significant effect on glycemic control and did not reduce HbA1C%","PeriodicalId":9369,"journal":{"name":"Bulletin of Faculty of Pharmacy, Cairo University","volume":"34 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Study the Effects of Taurine Oral Supplement used for Type 2 Diabetic Patients on Body Weight; Glycemic Control and Some Bone Mineralization Biochemical Markers\",\"authors\":\"Falah Hassan Sheri, Hiba Dawood, Jubran K Hassan, Qais A. Aljazaeari\",\"doi\":\"10.54634/2090-9101.1022\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Taurine is sulfur containing semi-essential amino acid that has important roles in many biological processes, but; its effects on glucose homeostasis, weight; growth and bone mineralization were not well defined in human. Objectives: evaluation the effects of oral taurine used for 3 months on bone mineralization biomarker; glycemic control and body weight in type II diabetic patients. Methods: interventional double-blind placebo-controlled study in which 80 patients with type2 diabetes mellitus (age range 45e55) assigned in either control (n 1⁄4 40) or study (n 1⁄4 40) group. The last group received 1000 mg capsule of taurine once a -d for three months. Parameters measured were serum calcium, 25(OH) vitamin D and osteocalcin, NTX-1; HbA1C% and Fasting blood glucose before and after 3 months. Results: Taurine led to significant (p < 0.05) rise in osteocalcin and significant lowering in Body weight and BMI and there were no significant changes in Serum Calcium; NTX-1; Vitamin D; HbA1C% and fasting blood glucose; all as compared with control values. Conclusion: 3 months of oral Taurine used in type II diabetic patients may modulate bone mineralization represented by elevation of osteocalcin; and reduction of body weight, but has no significant effect on glycemic control and did not reduce HbA1C%\",\"PeriodicalId\":9369,\"journal\":{\"name\":\"Bulletin of Faculty of Pharmacy, Cairo University\",\"volume\":\"34 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-12-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bulletin of Faculty of Pharmacy, Cairo University\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.54634/2090-9101.1022\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bulletin of Faculty of Pharmacy, Cairo University","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.54634/2090-9101.1022","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Study the Effects of Taurine Oral Supplement used for Type 2 Diabetic Patients on Body Weight; Glycemic Control and Some Bone Mineralization Biochemical Markers
Background: Taurine is sulfur containing semi-essential amino acid that has important roles in many biological processes, but; its effects on glucose homeostasis, weight; growth and bone mineralization were not well defined in human. Objectives: evaluation the effects of oral taurine used for 3 months on bone mineralization biomarker; glycemic control and body weight in type II diabetic patients. Methods: interventional double-blind placebo-controlled study in which 80 patients with type2 diabetes mellitus (age range 45e55) assigned in either control (n 1⁄4 40) or study (n 1⁄4 40) group. The last group received 1000 mg capsule of taurine once a -d for three months. Parameters measured were serum calcium, 25(OH) vitamin D and osteocalcin, NTX-1; HbA1C% and Fasting blood glucose before and after 3 months. Results: Taurine led to significant (p < 0.05) rise in osteocalcin and significant lowering in Body weight and BMI and there were no significant changes in Serum Calcium; NTX-1; Vitamin D; HbA1C% and fasting blood glucose; all as compared with control values. Conclusion: 3 months of oral Taurine used in type II diabetic patients may modulate bone mineralization represented by elevation of osteocalcin; and reduction of body weight, but has no significant effect on glycemic control and did not reduce HbA1C%